Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Trial in progress: SERANATA, a phase 3 randomized, placebo-controlled trial to evaluate inhaled seralutinib for treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Thursday, January 29, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The SERANATA trial is a phase 3 randomized, placebo-controlled study evaluating inhaled seralutinib for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). This trial aims to provide insights into the efficacy and safety of seralutinib, potentially offering a new therapeutic avenue for patients suffering from this condition. The study is currently in progress.
Price reaction · baseline $2.55 (2026-01-28 close) · hit pre-market · 2 other GOSS headline(s) in the window, move may be shared
day 0 close
-5.1%
day 1 · peak
-10.6%
day 3
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • The trial aims to address a significant medical need in PH-ILD.
  • Inhaled seralutinib may provide a new treatment option for patients.
  • The phase 3 trial design indicates a robust approach to evaluation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Trial in progress: SERANATA, a phase 3 randomized, placebo-controlled trial to evaluate inhaled seralutinib for treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the SERANATA trial about?

The SERANATA trial evaluates inhaled seralutinib for treating pulmonary hypertension associated with interstitial lung disease.

What phase is the SERANATA trial currently in?

The SERANATA trial is currently in phase 3.

What type of study design is used in the SERANATA trial?

The trial is a randomized, placebo-controlled study.

What condition is being targeted in the SERANATA trial?

The trial targets pulmonary hypertension associated with interstitial lung disease (PH-ILD).

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib PH-ILD pulmonary hypertension clinical trial
Last updated: Jan 29, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →